Asciminib
Last Updated: 02/24/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 291 publications
Advances of next-generation STAMP inhibitors in chronic myeloid leukemia.
Journal: Expert opinion on investigational drugs
Published: January 21, 2026
Specifically targeting the ABL myristoyl pocket: STAMP inhibitors for chronic myeloid leukemia.
Journal: Expert review of hematology
Published: January 07, 2026
Guideline for the diagnosis and treatment of chronic myeloid leukemia in China (2025)
Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: January 05, 2026
What is the role of asciminib in chronic myeloid leukemia?
Journal: Clinical advances in hematology & oncology : H&O
Published: December 29, 2025
Addressing unmet needs in chronic myeloid leukemia in chronic phase treated with two or more tyrosine kinase inhibitors: insights from literature and Indian clinical practice.
Journal: Expert review of hematology
Published: December 29, 2025
Natural Product-like Fragments Unlock Novel Chemotypes for a Kinase Target─Exploring Options beyond the Flatland.
Journal: Journal of chemical information and modeling
Published: December 23, 2025
Chronic myeloid leukemia presenting as B-lymphoblastic transformation after treatment for mucinous adenocarcinoma of unknown primary
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: December 07, 2025
Mini-hyper CVD-inotuzumab with asciminib as salvage therapy for ponatinib-refractory Ph + B-ALL and CML lymphoid blast crisis.
Journal: Leukemia & lymphoma
Published: November 18, 2025
Treatment of chronic myeloid leukemia chronic phase patients in third-line setting and beyond: recommendations from a Belgian expert panel in 2025.
Journal: Hematology (Amsterdam, Netherlands)
Published: October 31, 2025
Association of fibronectin 1 deregulation with tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Journal: Frontiers in cell and developmental biology
Published: October 15, 2025
Asciminib and inotuzumab ozogamicin: a new combination for highly refractory Ph-positive B-cell acute lymphoblastic leukemia.
Journal: Leukemia research reports
Published: October 02, 2025
Last Updated: 02/24/2026